JP2013517487A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013517487A5 JP2013517487A5 JP2012549291A JP2012549291A JP2013517487A5 JP 2013517487 A5 JP2013517487 A5 JP 2013517487A5 JP 2012549291 A JP2012549291 A JP 2012549291A JP 2012549291 A JP2012549291 A JP 2012549291A JP 2013517487 A5 JP2013517487 A5 JP 2013517487A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- cancer
- antigen
- cells
- associated carbohydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 166
- 201000011510 cancer Diseases 0.000 claims description 93
- 239000000427 antigen Substances 0.000 claims description 83
- 108091007433 antigens Proteins 0.000 claims description 83
- 102000036639 antigens Human genes 0.000 claims description 83
- 210000000130 stem cell Anatomy 0.000 claims description 60
- 150000001720 carbohydrates Chemical class 0.000 claims description 58
- 239000011230 binding agent Substances 0.000 claims description 46
- 210000004027 cell Anatomy 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 27
- 239000012634 fragment Substances 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 108090000288 Glycoproteins Proteins 0.000 claims description 6
- 102000003886 Glycoproteins Human genes 0.000 claims description 6
- 239000002771 cell marker Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 102100032912 CD44 antigen Human genes 0.000 claims description 5
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 5
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims description 5
- 108010058905 CD44v6 antigen Proteins 0.000 claims description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 4
- 101001133085 Homo sapiens Sialomucin core protein 24 Proteins 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 230000014509 gene expression Effects 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010057249 Phagocytosis Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000003837 Second Primary Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 2
- 230000006907 apoptotic process Effects 0.000 claims description 2
- 230000005907 cancer growth Effects 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- -1 multibody Proteins 0.000 claims description 2
- 210000004882 non-tumor cell Anatomy 0.000 claims description 2
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 230000008782 phagocytosis Effects 0.000 claims description 2
- 238000010186 staining Methods 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims 1
- 230000004186 co-expression Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000012217 radiopharmaceutical Substances 0.000 claims 1
- 229940121896 radiopharmaceutical Drugs 0.000 claims 1
- 230000002799 radiopharmaceutical effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29673810P | 2010-01-20 | 2010-01-20 | |
| EP10000527A EP2347769A1 (en) | 2010-01-20 | 2010-01-20 | Cancer stem cell markers and uses thereof |
| US61/296,738 | 2010-01-20 | ||
| EP10000527.1 | 2010-01-20 | ||
| PCT/EP2011/000217 WO2011089004A1 (en) | 2010-01-20 | 2011-01-20 | Cancer stem cell markers and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015253064A Division JP2016047848A (ja) | 2010-01-20 | 2015-12-25 | がん幹細胞マーカーおよびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013517487A JP2013517487A (ja) | 2013-05-16 |
| JP2013517487A5 true JP2013517487A5 (cg-RX-API-DMAC7.html) | 2014-02-06 |
Family
ID=42173400
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012549291A Ceased JP2013517487A (ja) | 2010-01-20 | 2011-01-20 | がん幹細胞マーカーおよびその使用 |
| JP2015253064A Withdrawn JP2016047848A (ja) | 2010-01-20 | 2015-12-25 | がん幹細胞マーカーおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015253064A Withdrawn JP2016047848A (ja) | 2010-01-20 | 2015-12-25 | がん幹細胞マーカーおよびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20120294859A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2347769A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2013517487A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102753199A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011208874B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012018132A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2786212A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011089004A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
| ES2442024T3 (es) | 2008-07-15 | 2014-02-07 | Academia Sinica | Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados |
| US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| WO2011130332A1 (en) | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
| AU2011295722B2 (en) | 2010-09-03 | 2016-04-21 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| WO2012039430A1 (ja) * | 2010-09-21 | 2012-03-29 | 株式会社Ｇｐバイオサイエンス | がん幹細胞の単離方法 |
| US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
| US9914956B2 (en) | 2012-08-18 | 2018-03-13 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
| EP2972390B1 (en) | 2013-03-14 | 2017-11-08 | The United States Of America, As Represented By The Sectretary, Department Of Health And Human Services | Hyposialylation disorders |
| WO2014210397A1 (en) | 2013-06-26 | 2014-12-31 | Academia Sinica | Rm2 antigens and use thereof |
| US9981030B2 (en) | 2013-06-27 | 2018-05-29 | Academia Sinica | Glycan conjugates and use thereof |
| EP3041484B1 (en) | 2013-09-06 | 2021-03-03 | Academia Sinica | Human inkt cell activation using glycolipids with altered glycosyl groups |
| HK1222569A1 (zh) | 2013-09-17 | 2017-07-07 | Obi Pharma, Inc. | 用於诱导免疫反应的糖疫苗组合物及其治疗癌症的用途 |
| JP2017507118A (ja) | 2014-01-16 | 2017-03-16 | アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ | がんの処置および検出のための組成物および方法 |
| US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| TWI687428B (zh) | 2014-03-27 | 2020-03-11 | 中央研究院 | 反應性標記化合物及其用途 |
| US10023651B2 (en) | 2014-04-18 | 2018-07-17 | The Research Foundation For The State University Of New York | Humanized anti-TF-antigen antibodies |
| EP3797793A1 (en) * | 2014-04-18 | 2021-03-31 | The Research Foundation of the State University of New York at Buffalo | Humanized anti-tf-antigen antibodies |
| CN103969437B (zh) * | 2014-04-22 | 2017-03-22 | 广州恒泰生物科技有限公司 | 用于卵巢癌早中期快速诊断试剂盒的制备方法 |
| US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| KR102512592B1 (ko) | 2014-05-27 | 2023-03-21 | 아카데미아 시니카 | 항-ｈｅｒ2 글리코항체 및 이의 용도 |
| EP3149036A4 (en) | 2014-05-27 | 2017-12-27 | Academia Sinica | Anti-cd20 glycoantibodies and uses thereof |
| CA2950423A1 (en) | 2014-05-27 | 2015-12-03 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| AU2015267044A1 (en) | 2014-05-28 | 2016-12-15 | Academia Sinica | Anti-TNF-alpha glycoantibodies and uses thereof |
| WO2016040369A2 (en) | 2014-09-08 | 2016-03-17 | Academia Sinica | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS |
| CA2967595A1 (en) | 2014-11-12 | 2016-05-19 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
| US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| CN107430127B (zh) * | 2015-01-24 | 2020-08-28 | 中央研究院 | 癌症标记及其使用方法 |
| KR102691114B1 (ko) | 2015-01-24 | 2024-08-01 | 아카데미아 시니카 | 신규한 글리칸 콘주게이트 및 이를 사용하는 방법 |
| US10493087B2 (en) | 2015-02-25 | 2019-12-03 | The United States of America, as represented by National Institute of Health | Sialylation-increasing therapies for diseases associated with oxidative stress |
| AR105910A1 (es) | 2015-09-04 | 2017-11-22 | Obi Pharma Inc | Matrices de glicano y método de uso |
| CA3002097A1 (en) | 2015-11-12 | 2017-05-18 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| WO2017100796A1 (en) * | 2015-12-11 | 2017-06-15 | SINACA, Academia | Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers |
| TW201808978A (zh) | 2016-03-08 | 2018-03-16 | 中央研究院 | N-聚醣及其陣列之模組化合成方法 |
| BR112018070097A2 (pt) | 2016-03-29 | 2019-02-12 | Obi Pharma, Inc. | anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| TWI697333B (zh) | 2016-04-22 | 2020-07-01 | 台灣浩鼎生技股份有限公司 | 經由Globo系列抗原之免疫活化或免疫調節之癌症免疫療法 |
| JP2019527690A (ja) | 2016-07-27 | 2019-10-03 | オービーアイ ファーマ，インコーポレイテッド | 免疫原性／治療用グリカン組成物およびその使用 |
| JP7121724B2 (ja) | 2016-07-29 | 2022-08-18 | オービーアイ ファーマ，インコーポレイテッド | ヒト抗体、医薬組成物及び方法 |
| US10538592B2 (en) | 2016-08-22 | 2020-01-21 | Cho Pharma, Inc. | Antibodies, binding fragments, and methods of use |
| EP3541847A4 (en) | 2016-11-17 | 2020-07-08 | Seattle Genetics, Inc. | COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE |
| EP3543337B1 (en) * | 2016-11-18 | 2022-04-20 | Astellas Pharma Inc. | Novel anti-human muc1 antibody fab fragment |
| WO2018094414A1 (en) | 2016-11-21 | 2018-05-24 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
| JP2020510671A (ja) | 2017-03-03 | 2020-04-09 | シアトル ジェネティックス， インコーポレイテッド | グリカン相互作用化合物および使用の方法 |
| WO2018178047A1 (en) * | 2017-03-29 | 2018-10-04 | Glycotope Gmbh | Multispecific antibody constructs binding to muc1 and cd3 |
| TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段 |
| CA3092470A1 (en) | 2018-02-27 | 2019-09-06 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
| PT110722B (pt) * | 2018-05-03 | 2021-08-17 | Instituto De Patologia E Imunologia Molecular Da Univ Do Porto Ipatimup | Uso de anticorpos para o antigénio thomsen-friedenreich num método e estojo para avaliação de instabilidade de microsatelites |
| JP7360766B2 (ja) | 2018-05-17 | 2023-10-13 | アステラス製薬株式会社 | 抗ヒトＭＵＣ１抗体Ｆａｂフラグメント、ペプチドリンカー及び／又は配位子を含む複合体 |
| US12479926B2 (en) | 2018-05-18 | 2025-11-25 | Daiichi Sankyo Co., Ltd. | Anti-MUC1 antibody-drug conjugate |
| WO2019222677A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| WO2020006176A1 (en) | 2018-06-27 | 2020-01-02 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
| AU2019297361B2 (en) | 2018-07-05 | 2024-06-27 | Incyte Corporation | Fused pyrazine derivatives as A2A / A2B inhibitors |
| JP7374544B2 (ja) | 2018-10-10 | 2023-11-07 | アステラス製薬株式会社 | 標識部－抗ヒト抗体Ｆａｂフラグメント複合体を含む医薬組成物 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| CN110161241A (zh) * | 2019-04-30 | 2019-08-23 | 丁晓昆 | 一种快速检测生物组织切片cosmc基因突变试剂盒 |
| CA3166533A1 (en) | 2020-01-03 | 2021-07-08 | Incyte Corporation | Anti-cd73 antibodies and uses thereof |
| JP2023509442A (ja) | 2020-01-03 | 2023-03-08 | インサイト・コーポレイション | Ｃｄ７３阻害剤とａ２ａ／ａ２ｂアデノシン受容体阻害剤の併用療法 |
| CN114315964B (zh) * | 2020-03-18 | 2023-06-13 | 北京鼎成肽源生物技术有限公司 | 一种输卵管癌靶标抗原组合、输卵管癌靶标抗原刺激培养的ctl细胞及其应用 |
| CN115916349A (zh) * | 2020-06-30 | 2023-04-04 | 葛莱高托普有限公司 | 针对Lewis Y的人源化抗体 |
| AU2021411952A1 (en) | 2020-12-29 | 2023-08-10 | Incyte Corporation | Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies |
| CA3224907A1 (en) * | 2021-07-16 | 2023-03-02 | Claude Perreault | Novel tumor-specific antigens for cancer stem cells and uses thereof |
| CN113804531B (zh) * | 2021-09-10 | 2024-02-06 | 北京大学 | 一种细胞高活性染色方法 |
| CN119955728A (zh) * | 2022-08-01 | 2025-05-09 | 首都医科大学附属北京胸科医院 | 恶性表型大细胞肺癌细胞株及其应用 |
| CN116718774A (zh) * | 2023-07-07 | 2023-09-08 | 杭州准星医学科技有限公司 | 一种用于肿瘤体外诊断的试剂盒及其使用方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6020145A (en) * | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
| DE10256900A1 (de) | 2002-11-29 | 2004-06-24 | Nemod Immuntherapie Ag | Tumorspezifische Erkennungsmoleküle |
| EP1654353B1 (en) | 2003-08-18 | 2013-05-22 | Glycotope GmbH | Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses threreof |
| US7374755B2 (en) * | 2004-07-26 | 2008-05-20 | The Research Foundation Of State University Of New York | Therapeutic use of anti-TF-Antigen antibody |
| CA2674269C (en) * | 2006-01-03 | 2018-06-12 | University Of Georgia Research Foundation, Inc. | Three component glycolipopeptides |
| WO2007140011A2 (en) * | 2006-05-26 | 2007-12-06 | The Government Of The United States Of America | Erythroid progenitor cells and methods for producing parvovirus b19 therein |
-
2010
- 2010-01-20 EP EP10000527A patent/EP2347769A1/en not_active Withdrawn
-
2011
- 2011-01-20 BR BR112012018132A patent/BR112012018132A2/pt active Search and Examination
- 2011-01-20 CN CN2011800065922A patent/CN102753199A/zh active Pending
- 2011-01-20 CA CA2786212A patent/CA2786212A1/en not_active Abandoned
- 2011-01-20 JP JP2012549291A patent/JP2013517487A/ja not_active Ceased
- 2011-01-20 AU AU2011208874A patent/AU2011208874B2/en not_active Ceased
- 2011-01-20 WO PCT/EP2011/000217 patent/WO2011089004A1/en not_active Ceased
- 2011-01-20 EP EP11703580A patent/EP2525832A1/en not_active Withdrawn
- 2011-01-20 US US13/574,260 patent/US20120294859A1/en not_active Abandoned
-
2015
- 2015-12-25 JP JP2015253064A patent/JP2016047848A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013517487A5 (cg-RX-API-DMAC7.html) | ||
| JP6491701B2 (ja) | 新規モジュレーターと使用の方法 | |
| JP7274469B2 (ja) | Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復 | |
| Münz et al. | Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies | |
| CN109970856B (zh) | 抗lag-3抗体及其用途 | |
| JP2022537053A (ja) | 抗ｔｉｇｉｔ抗体 | |
| JP2013544493A5 (cg-RX-API-DMAC7.html) | ||
| SA112330278B1 (ar) | مواد ضابطة جديدة وطرق للاستخدام | |
| JP2017149720A5 (cg-RX-API-DMAC7.html) | ||
| JP7450585B2 (ja) | ＣＤ６６ｃに特異的に結合する抗体およびその用途 | |
| WO2015161247A1 (en) | Humanized anti-c16orf54 antibodies and methods of use thereof | |
| WO2014068300A1 (en) | Anti-s100a4 antibody molecules and their uses | |
| JP2022507294A (ja) | Ｃｄｃｐ１－標的化療法 | |
| JP2020125352A (ja) | 抗−ｃｄ４３抗体およびその癌治療用途 | |
| CN110944665A (zh) | 用于预防或治疗肺癌的amhrii结合化合物 | |
| CN114040774A (zh) | 结合肿瘤组织用于诊断和治疗的抗体 | |
| CN117304325A (zh) | B7h3抗体及其用途 | |
| JP2021523193A (ja) | 骨髄由来抑制細胞関連疾患の予防および治療用途 | |
| Schmetzer et al. | Detection of circulating tumor-associated antigen depends on the domains recognized by the monoclonal antibodies used: N-terminal trimmed EpCAM-levels are much higher than untrimmed forms | |
| BR112020023380A2 (pt) | anticorpo isolado ou um fragmento de ligação ao antígeno do mesmo, polinucleotídeo isolado, vetor recombinante, célula hospedeira, método para produzir um anticorpo ou um fragmento de aglutinação ao antígeno do mesmo e para tratar ou detectar câncer, conjugado de anticorpo ,e, composição farmacêutica | |
| CN114907478A (zh) | 结合lag-3的抗体及其用途 | |
| WO2024077774A1 (zh) | 一种多功能重组抗体及其制备方法和应用 | |
| TW202540179A (zh) | 抗dll3抗體以及製造與使用其之方法 | |
| CN118891287A (zh) | 抗cd73的抗体及其应用 | |
| HK40009518B (en) | Anti-lag-3 antibody and the use thereof |